Bush Signs Bill Granting FDA $150 Million - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bush Signs Bill Granting FDA $150 Million


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (June 30)—President Bush signed H.R. 2642, the Supplemental Appropriations Act of 2008, which provides $150 million to the US Food and Drug Administration for medical-safety and drug-safety activities. The funds will be available until Sept. 30, 2009 and include:

  • $28 million for the Center for Drug Evaluation and Research
  • $12.7 million for the Center for Biologics Evaluation and Research
  • $20 million for the Center for Devices and Radiological Health
  • $3.4 million for the National Center for Toxicological Research
  • $12.9 million for other activities, including the Office of the Commissioner, the Office of Scientific and Medical Programs, the Office of Policy, Planning and Preparedness, the Office of International and Special Programs, and the Office of Operations.

The act also imposes a moratorium on six Medicaid rules that the Bush administration had issued. The Administration had proposed to reduce federal contributions for school-based services such as transportation for children with special needs, rehabilitation services, targeted case management for people with physical or mental disorders, hospital cost limits, and graduate medical education. The regulations would have shifted millions of dollars in healthcare costs to the states, but they were reversed before the bill reached Bush’s desk.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here